Augmedix, Inc. (AUGX)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Augmedix, Inc. (AUGX) trades at $2.35 with AI Score 58/100 (Grade B). Augmedix, Inc. provides remote medical documentation and live clinical support services, leveraging technology to streamline healthcare workflows. Market cap: $115.91M, Sector: Healthcare.
Price live · AI analysis from Mar 15, 2026Analyst Coverage for AUGX: AUGX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates AUGX against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
AUGX: the 4 perspectives are evenly split. Dominant signal: Seth Klarman bearish.
How is this calculated? →Augmedix, Inc. (AUGX) Healthcare & Pipeline Overview
Augmedix, Inc. offers remote medical documentation solutions and live clinical support, enhancing clinician efficiency through its Augmedix Live and Notes platforms. Serving health systems and specialty groups, the company leverages mobile devices to streamline pre-, during-, and post-visit documentation, positioning itself within the growing healthcare information services market.
What Is the Investment Thesis for AUGX?
Augmedix, Inc. presents an intriguing investment opportunity within the healthcare information services sector. The company's focus on leveraging technology to streamline medical documentation addresses a significant pain point for healthcare providers. Key value drivers include the increasing adoption of telehealth and remote patient monitoring, which drives demand for efficient documentation solutions. Growth catalysts include expanding partnerships with health systems and specialty groups, as well as the potential for international expansion. However, the company's negative profit margin of -42.7% and a P/E ratio of -5.38 highlight the risks associated with profitability and valuation. Investors should closely monitor the company's ability to scale its operations, improve its financial performance, and navigate the competitive landscape.
Based on FMP financials and quantitative analysis
AUGX Key Highlights
- Market capitalization of $115.91M indicates the company's current valuation in the market.
- Gross margin of 48.0% reflects the company's ability to generate revenue after accounting for the cost of goods sold.
- Negative profit margin of -42.7% suggests the company is currently operating at a loss.
- Beta of -0.19 indicates the stock is less volatile than the overall market.
- The company employs 1430 individuals, reflecting its operational scale and service delivery capacity.
Who Are AUGX's Competitors?
AUGX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CYT Cyteir Therapeutics, Inc. | $3.02 | -2.27% | $108.71M | 47 |
| DBTX Decibel Therapeutics, Inc. | $4.91 | -0.81% | $123.37M | 44 |
| FVE Five Star Senior Living Inc. | $2.94 | +2.44% | $98.39M | 39 |
| GRAY Graybug Vision, Inc. | $5.50 | -10.80% | $120.98M | 44 |
| NEUE NeueHealth, Inc. | $6.75 | +0.00% | $60.94M | 42 |
| CARL CARLSMED, INC. | $11.90 | +4.94% | $323.50M | 70 |
| HNGE Hinge Health, Inc. | $89.42 | +6.39% | $6.92B | 68 |
| VRHI Veri Medtech Holdings Inc. | $1.95 | +0.00% | $39.09M | 67 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are AUGX's Key Strengths?
- Proprietary technology platform for remote medical documentation
- Established relationships with health systems and specialty groups
- Expertise in healthcare workflows and regulatory compliance
- Scalable business model with recurring revenue streams
What Are AUGX's Weaknesses?
- Negative profit margin and ongoing losses
- Reliance on a limited number of large customers
- Competition from established players and emerging technology companies
- Potential for cybersecurity breaches and data privacy violations
What Could Drive AUGX Stock Higher?
- Potential new partnerships with large hospital networks by Q4 2026, expanding market reach.
- Increasing adoption of telehealth services driving demand for remote documentation solutions.
- Focus on AI-driven automation to improve efficiency and reduce costs.
What Are the Key Risks for AUGX?
- Financial-distress signal — its Altman Z-Score of -2.55 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Changes in healthcare regulations impacting reimbursement models.
- Increased competition from other healthcare technology providers.
- Data security and privacy concerns related to handling sensitive patient information.
What Are the Growth Opportunities for AUGX?
- Expansion into new therapeutic areas represents a significant growth opportunity for Augmedix. By tailoring its solutions to specific medical specialties, such as cardiology, oncology, or orthopedics, the company can address the unique documentation needs of these areas. This targeted approach can drive adoption and increase revenue within these specialized markets. The market size for each therapeutic area varies, but the combined potential represents a substantial growth opportunity over the next 3-5 years.
- Geographic expansion beyond the United States offers another avenue for growth. The demand for efficient medical documentation solutions is global, and Augmedix can leverage its technology platform to serve healthcare providers in other countries. Initial target markets could include Canada, the United Kingdom, and Australia, where healthcare systems are similar to the United States. This expansion could occur within the next 2-4 years, contingent on regulatory approvals and market entry strategies.
- Strategic partnerships with EHR vendors can accelerate Augmedix's market penetration. By integrating its solutions with leading EHR platforms, the company can seamlessly embed its services into existing healthcare workflows. This integration can streamline the user experience and drive adoption among healthcare providers who are already using these EHR systems. These partnerships could be established within the next 1-2 years, providing immediate access to a large customer base.
- Development of AI-powered documentation tools can enhance the efficiency and accuracy of Augmedix's solutions. By leveraging artificial intelligence and machine learning, the company can automate certain aspects of the documentation process, such as data extraction and summarization. This can further reduce the administrative burden on clinicians and improve the quality of medical notes. The development and deployment of these AI tools could occur within the next 2-3 years, providing a significant competitive advantage.
- Offering specialized solutions for telehealth platforms represents a growing opportunity. As telehealth adoption continues to increase, the need for efficient documentation solutions tailored to virtual care settings is becoming more critical. Augmedix can develop specialized features and workflows that address the unique challenges of telehealth, such as remote patient monitoring and virtual consultations. This offering could be launched within the next 1-2 years, capitalizing on the rapid growth of the telehealth market.
What Opportunities Does AUGX Have?
- Expansion into new therapeutic areas and geographic markets
- Strategic partnerships with EHR vendors and telehealth platforms
- Development of AI-powered documentation tools
- Increasing adoption of telehealth and remote patient monitoring
What Threats Does AUGX Face?
- Changes in healthcare regulations and reimbursement policies
- Economic downturn and reduced healthcare spending
- Technological obsolescence and disruption from new entrants
- Data security breaches and privacy concerns
What Are AUGX's Competitive Advantages?
- Proprietary technology platform for remote medical documentation.
- Established relationships with health systems and specialty groups.
- Expertise in healthcare workflows and regulatory compliance.
- Data network effects: As more clinicians use the platform, the AI models improve, enhancing the service.
What Does AUGX Do?
Founded in 2013 and headquartered in San Francisco, California, Augmedix, Inc. is dedicated to transforming healthcare delivery through its remote medical documentation and live clinical support services. The company's core offering revolves around its Augmedix platform, which includes Augmedix Live and Augmedix Notes solutions. These solutions address critical documentation needs at every stage of the patient visit, from pre-visit preparation, including pre-charting and digitization of patient history, to during-visit support with medical notes, care gap reminders, and after-visit summaries encompassing coding, orders, and referrals. Augmedix enables clinicians to access these applications via mobile devices, including smartphones and Google Glass, promoting flexibility and accessibility. Augmedix partners with health systems and specialty groups across the United States, aiming to alleviate administrative burdens on healthcare professionals, improve documentation accuracy, and ultimately enhance the patient care experience. The company's focus on technology-driven solutions positions it within the rapidly evolving healthcare information services sector, where efficiency and data management are increasingly vital.
What Products and Services Does AUGX Offer?
- Provides remote medical documentation solutions to healthcare providers.
- Offers live clinical support services to physicians and other clinicians.
- Streamlines pre-visit documentation, including pre-charting and patient history digitization.
- Facilitates during-visit documentation, such as medical notes and care gap reminders.
- Handles post-visit documentation, including coding, orders, and referrals.
- Enables clinicians to access applications through mobile devices like smartphones and Google Glass.
How Does AUGX Make Money?
- Augmedix generates revenue by providing subscription-based access to its platform.
- The company charges fees for its remote medical documentation and live clinical support services.
- Pricing models may vary based on the number of clinicians served and the volume of documentation processed.
What Industry Does AUGX Operate In?
Augmedix operates within the healthcare information services industry, a sector experiencing rapid growth driven by the increasing adoption of electronic health records (EHRs), telehealth, and value-based care models. The market is characterized by intense competition among established players and emerging technology companies. Augmedix differentiates itself through its focus on remote medical documentation and live clinical support, catering to the growing demand for efficient and streamlined healthcare workflows. The industry is projected to continue its growth trajectory, fueled by the need to reduce administrative burdens on healthcare providers and improve patient outcomes.
Who Are AUGX's Key Customers?
- Health systems seeking to improve clinician efficiency and reduce administrative burdens.
- Specialty groups looking to streamline documentation workflows and enhance patient care.
- Individual physicians and clinicians seeking remote support for medical documentation tasks.
Augmedix, Inc. Financial Trajectory
Augmedix, Inc. (AUGX) reported $13.7M in revenue for Q2 2024, reflecting 1.4% growth compared to the prior quarter. The company recorded a net loss of $8.4M, with diluted EPS of $-0.16.
Company Profile
Augmedix, Inc. operates in the Medical - Healthcare Information Services industry within the Healthcare sector. It is headquartered in San Francisco, US. The company is led by CEO Emmanuel Krakaris. AUGX has traded publicly since 2021.
How Augmedix, Inc. Is Valued
Augmedix, Inc. carries a market capitalization of $115.91M, placing it in the micro-cap category. Relative to its peer group, AUGX's quantitative score of 58/100 is above the peer average of 43/100.
Key Financial Metrics
Return on assets is -28.7%, showing how much profit it generates from its asset base. Its free cash flow yield is -16.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.41 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -18.6%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 2/9Financial Health
Augmedix, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -2.55 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project Augmedix, Inc. revenue of about $62.0M for fiscal 2026, with EPS near $-0.35.
AUGX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Proprietary technology platform for remote medical documentation
- Established relationships with health systems and specialty groups
- Expertise in healthcare workflows and regulatory compliance
- Scalable business model with recurring revenue streams
Bear Case
- Negative profit margin and ongoing losses
- Reliance on a limited number of large customers
- Competition from established players and emerging technology companies
- Potential for cybersecurity breaches and data privacy violations
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2024 | $14M | -$8M | -$0.16 |
| Q1 2024 | $13M | -$6M | -$0.12 |
Based on FMP financials and quantitative analysis
AUGX Latest News
No recent news available for AUGX.
AUGX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for AUGX.
Price Targets
Wall Street price target analysis for AUGX.
AUGX MoonshotScore
What does this score mean?
The MoonshotScore rates AUGX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Emmanuel Krakaris
CEO
Emmanuel Krakaris serves as the CEO of Augmedix, Inc., leading the company's strategic direction and operational execution. His background includes extensive experience in healthcare technology and management. Before joining Augmedix, he held leadership positions at various healthcare companies, focusing on innovation and growth. He brings a wealth of knowledge in healthcare information services and a commitment to improving patient care through technology.
Track Record: Since assuming the role of CEO, Emmanuel Krakaris has focused on expanding Augmedix's market reach and enhancing its technology platform. Key achievements include securing partnerships with major health systems and driving innovation in AI-powered documentation tools. Under his leadership, the company has navigated the challenges of the evolving healthcare landscape and positioned itself for future growth.
Augmedix, Inc. Healthcare Stock: Key Questions Answered
What does Augmedix, Inc. do?
Augmedix, Inc. provides remote medical documentation and live clinical support services to healthcare providers. Its platform, including Augmedix Live and Augmedix Notes, streamlines the documentation process across pre-visit, during-visit, and post-visit stages. By leveraging technology and remote specialists, Augmedix aims to reduce the administrative burden on clinicians, allowing them to focus more on patient care. The company serves health systems and specialty groups, offering solutions accessible through mobile devices.
What are the main risks for AUGX?
The main risks for Augmedix, Inc. include its negative profit margin and ongoing losses, which raise concerns about its long-term financial sustainability. Increased competition from established players and emerging technology companies could erode its market share. Changes in healthcare regulations and reimbursement policies could also negatively impact its revenue. Additionally, data security breaches and privacy concerns pose a significant threat to its reputation and operations. Investors should carefully assess these risks before investing in AUGX.
What are the key factors to evaluate for AUGX?
Augmedix, Inc. (AUGX) holds an AI score of 58/100 (moderate). Not financial advice.
How frequently does AUGX data refresh on this page?
AUGX prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven AUGX's recent stock price performance?
Augmedix, Inc. (AUGX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary technology platform for remote medical documentation. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider AUGX overvalued or undervalued right now?
Valuing Augmedix, Inc. (AUGX) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying AUGX?
Before investing in Augmedix, Inc. (AUGX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding AUGX to a portfolio?
Key strength of Augmedix, Inc. (AUGX): Proprietary technology platform for remote medical documentation. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the most recent available information.
- AI analysis is pending and may provide further insights.